Rivaroxaban Patent Status
Rivaroxaban, the active ingredient in Xarelto, faces patent expiration in the US by late 2024 for key composition-of-matter patents, enabling generic entry.[1] Bayer and Janssen hold the primary patents, with US Patent 6,957,131 (covering the compound) expiring January 1, 2024, after pediatric exclusivity extension.[2]
When Do Key Patents Expire?
- Core compound patent (US 6,957,131): Expired January 1, 2024.[2]
- Polymorph/salt form patents (e.g., US 7,157,466): Expire through 2026.[2]
- Method-of-use patents extend protection to 2033 in some cases, but generics can launch for approved indications post-compound expiry.[1][2]
Pediatric exclusivity added six months to several patents, pushing the first wave of generics to Q1 2024, though litigation delayed some approvals.[2]
Generic Launches and FDA Approvals
FDA approved the first rivaroxaban generics in late 2023, with launches starting January 2024 from Sandoz, Mylan, and others after settling Paragraph IV challenges.[1][2] More ANDAs are approved, targeting stroke prevention and DVT treatment.
Ongoing Litigation and Delays
Bayer/Janssen sued generic makers like Apotex and Alembic over secondary patents, resulting in settlements allowing at-risk launches from 2024-2028.[2] No major blocks remain for basic generics, but some formulations face suits into 2026.
Impact on Xarelto Sales
Xarelto generated $1.5B in US sales in 2023; generics could cut Bayer's revenue by 70-80% within a year.[1] Europe saw generics enter earlier, in 2020.
International Patent Timelines
EU compound patent expired 2018, with generics widespread.[3] Japan expiry is 2025; China allows generics post-2023 regional patents.[3]
[1]: DrugPatentWatch.com/rivaroxaban
[2]: FDA Orange Book for rivaroxaban
[3]: EMA patent register